Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pharmacokinetic-guided Dosing of Emicizumab in Congenital Haemophilia A Patients - The DosEmi Study

NCT06320626 is registered in ClinicalTrials.gov with Kathelijn Fischer as lead sponsor.

NCT NCT06320626
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06320626 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pharmacokinetic-guided Dosing of Emicizumab in Congenital Haemophilia A Patients - The DosEmi Study
Lead sponsor
Kathelijn Fischer
Phase
Phase 4
Overall status
Recruiting
Start date
September 8, 2022
Completion date
August 31, 2026
Enrollment
95 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

adolescent, adult, child, hemophilia a with inhibitor, hemophilia a without inhibitor, hemophilia a, severe